River Stone Biotech

River Stone Biotech is a private, Copenhagen-based company leveraging a hybrid synthetic biology and chemistry platform to reinvent the supply chain for high-value, complex APIs. Its initial commercial focus is on producing opioid use disorder treatments and prostaglandins, aiming to reduce cost, complexity, and environmental impact. The company has secured key patents, published significant research, and announced a global commercial launch as of late 2023, positioning it as a disruptive specialty API manufacturer.

Hybrid platform integrating microbial fermentation (synthetic biology) with optimized synthetic chemistry to manufacture complex small-molecule APIs. Uses engineered microbes to produce key intermediates, which are then converted via streamlined chemical processes for sustainable, scalable, and cost-effective production.

RSB competes with traditional chemical API manufacturers and suppliers that use plant extraction or full chemical synthesis. It also competes with other synthetic biology startups targeting complex molecule production. Its differentiation lies in its hybrid biology-chemistry approach, aiming for a better cost structure and sustainability profile than pure chemical routes and potentially faster pathway development than biology-only approaches.